Pazopanib therapy can cause severe but potentially reversible left ventricular systolic dysfunction, emphasizing the need for close echocardiographic monitoring in cardio-oncology patients.
Supports vigilant cardiac monitoring on pazopanib; hypothesis-generating for reversibility and leaves optimal surveillance protocols open.
Pazopanib is a tyrosine kinase inhibitor used for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma. We describe a case report of a patient with spindle cell sarcoma who developed severe left ventricular systolic dysfunction after starting pazopanib therapy with subsequent recovery of left ventricular ejection fraction upon stopping therapy.
No takes yet. Share an insight, caveat, or question.
Gajjar et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: